Structures by: Leach A. G.
Total: 8
C19H20O3S
C19H20O3S
Organic & Biomolecular Chemistry (2009) 7, 23 4842-4852
a=5.6114(4)Å b=11.6946(9)Å c=25.505(2)Å
α=90.00° β=90.00° γ=90.00°
4-(6-fluoro-5-(5-(2,4,5- trifluorophenylamino)-1,3,4-oxadiazole-2- carboxamido)pyridin-2-yloxy)cyclo- hexanecarboxylic acid
C21H17F4N5O5
MedChemComm (2013) 4, 1 151
a=29.7773(14)Å b=6.3200(3)Å c=23.2587(11)Å
α=90.00° β=100.671(3)° γ=90.00°
Tetrahydrofuran-3-yl 4-(5-((3-cyanopyridin-4-yl) methoxy)pyrimidin-2-yl)piperazine-1-carboxylate
C20H22N6O4
MedChemComm (2013) 4, 1 95
a=5.2885(7)Å b=11.2227(15)Å c=16.881(2)Å
α=85.165(6)° β=83.895(6)° γ=76.853(5)°
AZ12408627 acetic acid solvate, Analysis Report AZ SBBG: 2005-39-301, DGAT1 project
C23H21F3N4O4,C2H4O2
MedChemComm (2013) 4, 1 151
a=5.1885(5)Å b=11.4587(10)Å c=21.469(2)Å
α=75.373(5)° β=86.058(5)° γ=83.124(4)°
4-((2-(4-(5-isopropyl-1,2,4-oxadiazol-3-yl)-2-methylpiperazin- 1-yl)pyrimidin-5-y
C21H20N8O2,3(H)
MedChemComm (2012) 3, 5 600
a=9.1873(3)Å b=10.2806(2)Å c=11.8644(3)Å
α=94.876(1)° β=103.767(2)° γ=102.245(1)°
4-((2-(4-(5-(difluoromethyl)-1,2,4-oxadiazol-3-yl)-2- methylpiperazin-1-yl) pyrimidin-5-yloxy)methyl)nicotinonitrile
C19H18F2N8O2
MedChemComm (2012) 3, 5 600
a=6.8535(17)Å b=11.759(3)Å c=24.167(8)Å
α=90.00° β=90.00° γ=90.00°
C21H26O10S
C21H26O10S
Chemical communications (Cambridge, England) (2009) 39 5841-5843
a=5.8256(4)Å b=14.5183(12)Å c=27.760(3)Å
α=90.00° β=90.00° γ=90.00°
C21H21N4O4
C21H21N4O4
Journal of the American Chemical Society (2003) 125, 4271-4278
a=7.017(2)Å b=10.987(4)Å c=12.948(4)Å
α=93.988(7)° β=104.824(6)° γ=93.071(6)°